Stocktoria
Krystal Biotech, Inc. KRYS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2017-09-20
Krystal Biotech, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 41.5% | 22.6% | -216.2% | — | — |
| Net margin | 52.6% | 30.7% | 21.6% | — | — |
| FCF margin | 48.5% | 41.0% | -198.4% | — | — |
| Return on assets | 15.4% | 8.4% | 1.3% | -25.1% | -11.1% |
| Return on equity | 16.8% | 9.4% | 1.4% | -26.8% | -11.7% |
| Current ratio | 9.95 | 7.28 | 17.76 | 13.30 | 17.18 |
| Revenue growth | 33.9% | 473.0% | — | — | — |
Source: SEC EDGAR filings · CIK 0001711279 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.